Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension

by Baumgart, Peter, Naudts, Ingomar, Kiel, Gerhard
Published in Pragmat Obs Res (2011)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

by Gitt, Anselm K, Baumgart, Peter, Bramlage, Peter, Mahfoud, Felix, Potthoff, Sebastian A, Senges, Jochen, Schneider, Steffen, Buhck, Hartmut, Schmieder, Roland E
Published 2013

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights...

by Bramlage, Peter, Schmieder, Roland E., Gitt, Anselm K., Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ouarrak, Taoufik, Ehmen, Martina, Potthoff, Sebastian A.
Published in Trials (2015)

Functional and Structural Profiling of the Human Thrombopoietin Gene Promoter

by Dördelmann, Corinna, Telgmann, Ralph, Brand, Eva, Hagedorn, Claudia, Schröer, Bianca, Hasenkamp, Sandra, Baumgart, Peter, Kleine-Katthöfer, Peter, Paul, Martin, Brand-Herrmann, Stefan-Martin
Published 2008

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry

by Gitt, Anselm K., Bramlage, Peter, Potthoff, Sebastian A., Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ehmen, Martina, Ouarrak, Taoufik, Senges, Jochen, Schmieder, Roland E.
Published in BMC Cardiovasc Disord (2016)

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective EAR...

by Schmieder, Roland E., Potthoff, Sebastian A., Bramlage, Peter, Baumgart, Peter, Mahfoud, Felix, Buhck, Hartmut, Ouarrak, Taoufik, Ehmen, Martina, Senges, Jochen, Gitt, Anselm K.
Published in J Clin Hypertens (Greenwich) (2015)